Short answer
TuHURA Biosciences, Inc./NV (HURA) filed an 8-K current report with the SEC on August 14, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results covered three months ended June 30, 2026.
TuHURA Biosciences, Inc./NV 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results covered three months ended June 30, 2026
- Corporate update included alongside quarterly results
- Detailed financial figures and management commentary provided in Exhibit 99.1
- Disclosure furnished under Item 2.02, not deemed filed or incorporated by reference universally
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 operating cash burn increased to $13.0M from $10.9M, highlighting continued financing dependence
- Cash totaled $1.0M at June 30, while $5.7M was drawn from the Parkview facility, including $2.15M after quarter-end
- $50M credit facility offers non-convertible funding at 12% interest, with principal due April 21, 2031
- TBS-2025 IND filing supports planned Phase 1b/2 initiation in 2H 2026 for mutNPM1 relapsed/refractory AML
- Key catalysts include potential orphan-drug designations, preliminary VISTA data in 1H 2027, and IFx-2.0 Phase 3 enrollment completion in 2H 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TuHURA Biosciences, Inc./NV 8-K filings
Get the next HURA 8-K as it lands
Follow HURA for push alerts, or ask the research agent what this filing means.